Drugs / GPC3-CART cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04506983 | Jun 2022 → Jun 2023 | hepatocellular carcinoma | Beijing Tsinghua Chang Gung Hospital | Suspended | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06641453 | Nov 2024 → Nov 2027 expected | hepatocellular carcinoma | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03130712 | Apr 2017 → Mar 2018 | hepatocellular carcinoma | Shanghai GeneChem Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02715362 | Mar 2016 → Jul 2018 | hepatocellular carcinoma | Shanghai GeneChem Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05620706 | Nov 2022 → Oct 2025 overdue | hepatocellular carcinoma | Shenzhen University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPC3-CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04506983 ↗ |
| Action | Deplete | “target and destroy cancer cells” NCT06641453 ↗ |
| Modality | Cell therapy | “T cells are activated and then re-engineered to express chimeric antigen receptors (CARs) specific for GPC3.” NCT02715362 ↗ |
| Route | Other | “transcatheter arterial infusion” NCT02715362 ↗ |
| Target | GPC3 | “GPC3-targeted chimeric antigen receptor (CAR) T-cell therapy” NCT06641453 ↗ |